Given the success of the Research Topic ‘Epigenetics in Cancer: Mechanisms and Drug Development', we are pleased to launch a second volume for further submissions.
These are exciting times for discovering the biological scope and the mechanisms of action for DNA and RNA molecules, which have a great impact on tumors. Epigenetic mechanisms, such as posttranslational modifications of chromatin (DNA and histones), play pivotal roles in development, cell differentiation, and cell identity. Inappropriate regulation of epigenetic mechanisms has been implicated in human tumors. Moreover, there has been a recent explosion of activity in the fields of RNA epigenetics and non-coding RNAs, which have become integral parts of the field of gene expression.
Volume II of the Research Topic will integrate different research directions including transcription and chromatin roles in gene regulation, DNA modifications, RNA epigenetics, non-coding RNA, and epigenomic methods. In addition to bringing the newest findings on epigenetic mechanisms, a special focus will be given to novel and promising therapeutic drugs aimed at reversing specific epigenetic alterations.
Subtopics of interest include, but are not limited to:
•Clinical utility of epigenetic and epigenomic markers.
•DNA methylation, histone modifications, and nucleosome positioning in tumors.
•Non-coding RNAs, including miRNAs, IncRNAs, circRNAs, piRNAs in tumors.
•Extrachromosomal DNA (ecDNA) in cancer.
•RNA modification, especially RNA methylation, alternative splicing, and transcription‐wide RNA modification in cancer.
Given the success of the Research Topic ‘Epigenetics in Cancer: Mechanisms and Drug Development', we are pleased to launch a second volume for further submissions.
These are exciting times for discovering the biological scope and the mechanisms of action for DNA and RNA molecules, which have a great impact on tumors. Epigenetic mechanisms, such as posttranslational modifications of chromatin (DNA and histones), play pivotal roles in development, cell differentiation, and cell identity. Inappropriate regulation of epigenetic mechanisms has been implicated in human tumors. Moreover, there has been a recent explosion of activity in the fields of RNA epigenetics and non-coding RNAs, which have become integral parts of the field of gene expression.
Volume II of the Research Topic will integrate different research directions including transcription and chromatin roles in gene regulation, DNA modifications, RNA epigenetics, non-coding RNA, and epigenomic methods. In addition to bringing the newest findings on epigenetic mechanisms, a special focus will be given to novel and promising therapeutic drugs aimed at reversing specific epigenetic alterations.
Subtopics of interest include, but are not limited to:
•Clinical utility of epigenetic and epigenomic markers.
•DNA methylation, histone modifications, and nucleosome positioning in tumors.
•Non-coding RNAs, including miRNAs, IncRNAs, circRNAs, piRNAs in tumors.
•Extrachromosomal DNA (ecDNA) in cancer.
•RNA modification, especially RNA methylation, alternative splicing, and transcription‐wide RNA modification in cancer.